

BSI Standards Publication

Molecular in-vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood

Part 3: Isolated circulating cell free DNA from plasma



National foreword

This British Standard is the UK implementation of EN ISO 20186-3:2019. It is identical to ISO 20186-3:2019. It supersedes PD CEN/TS 16835-3:2015, which is withdrawn.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2019 Published by BSI Standards Limited 2019

ISBN 978 0 539 12203 9

ICS 11.100.10; 11.100.30

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 October 2019.

Amendments/corrigenda issued since publication

Date	Text affected
30 November 2019	Implementation of CEN correction notice 20 October 2019: DOW corrected

EN ICO 20106_2

This is a preview of "BS EN ISO 20186-3:20...". Click here to purchase the full version from the ANSI store.

EUROPÄISCHE NORM

October 2019

ICS 11.100.10

English Version

Molecular in-vitro diagnostic examinations - Specifications for pre-examination processes for venous whole blood - Part 3: Isolated circulating cell free DNA from plasma (ISO 20186-3:2019)

Analyses de diagnostic moléculaire in vitro -Spécifications relatives aux processus préanalytiques pour le sang total veineux - Partie 3: ADN libre circulant extrait du plasma (ISO 20186-3:2019) Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für venöse Vollblutproben - Teil 3: Aus Plasma isolierte zirkulierende zellfreie DNA (ISO 20186-3:2019)

This European Standard was approved by CEN on 14 September 2019.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION COMITÉ EUROPÉEN DE NORMALISATION EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 20186-3:2019) has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by April 2020, and conflicting national standards shall be withdrawn at the latest by October 2022.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes CEN/TS 16835-3:2015.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 20186-3:2019 has been approved by CEN as EN ISO 20186-3:2019 without any modification.

Coi	Contents		
Fore	word		iv
Intro	oductio	on	v
1	Scop	oe	1
2	Norn	native references	1
3		ns and definitions	
4		eral consideration	
5	Outside the laboratory		
	5.1	Specimen collection	
		5.1.1 Information about the specimen donor/patient	
		5.1.2 Selection of the venous whole blood collection tube by the laboratory5.1.3 Venous whole blood collection from the donor/patient and stabilization	6
		procedures	6
		collection facility	7
	5.2	Transport requirements	
6	Inside the laboratory		8
	6.1	Specimen reception	
	6.2	Storage requirements for blood specimens	
	6.3	Plasma preparation	
	6.4	Storage requirements for plasma samples	
	6.5	Isolation of the ccfDNA	
		6.5.1 General	
		6.5.2 Using blood collection tubes with stabilizers6.5.3 Using blood collection tubes without stabilizers	
	6.6	Quantity and quality assessment of isolated ccfDNA	11
	6.7 Storage of isolated ccfDNA		11
	0.7	6.7.1 General	
		6.7.2 ccfDNA isolated with commercially available kits	
		6.7.3 ccfDNA isolated with the laboratory's own protocols	
Anno	ex A (in	nformative) Impact of pre-examination process steps on circulating cell free DN	A
	•	ïles in venous whole blood plasma	
Bibli	iograph	hy	16

ISO 20186-3:2019(E)

This is a preview of "BS EN ISO 20186-3:20...". Click here to purchase the full version from the ANSI store.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

A list of all parts in the ISO 20186 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

Molecular in vitro diagnostics has enabled a significant progress in medicine. Further progress is expected by new technologies analysing profiles of nucleic acids, proteins, and metabolites in human tissues and body fluids. However, the profiles of these molecules can change drastically during the pre-examination process, including the specimen collection, transport, storage and processing. Consequently, this makes the outcome from diagnostics or research unreliable or even impossible because the subsequent examination might not determine the real situation in the patient, but an artificial profile generated during the pre-examination processes.

Circulating cell free DNA (ccfDNA) profiles can change significantly after blood collection (e.g. release of genomic DNA from cells in blood, ccfDNA degradation and fragmentation and ccfDNA quantity change). Therefore, special measures need to be taken to secure good quality specimens for ccfDNA examination. Studies have been undertaken to determine the important influencing factors^[23].

Standardization of the entire workflow from specimen collection to the ccfDNA examination is needed.

This document standardizes the steps of the pre-examination phase of circulating cell free DNA prepared from plasma of venous whole blood.

In this document, the following verbal forms are used:

- "shall" indicates a requirement;
- "should" indicates a recommendation;
- "may" indicates a permission;
- "can" indicates a possibility or a capability.

Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for venous whole blood —

Part 3:

Isolated circulating cell free DNA from plasma

1 Scope

This document provides recommendations and requirements on the handling, storage, processing and documentation of venous whole blood specimens intended for circulating cell free DNA (ccfDNA) examination during the pre-examination phase before an analytical test is performed. This document covers specimens collected in venous whole blood collection tubes.

This document is applicable to any molecular in vitro diagnostic examination performed by medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities.

Different dedicated measures are taken for stabilizing blood genomic DNA, which are not described in this document. Blood genomic DNA is covered in ISO 20186-2.

Different dedicated measures are taken for preserving DNA in circulating exosomes, which are not described in this document.

NOTE ccfDNA obtained from blood by the procedures cited in this document can contain DNA originally present in exosomes [3][9].

DNA in pathogens present in blood is not covered by this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 15189:2012, Medical laboratories — Requirements for quality and competence

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at https://www.iso.org/obp
- IEC Electropedia: available at http://www.electropedia.org/

3.1 analyte

component represented in the name of a measurable quantity

[SOURCE: ISO 17511:2003, 3.2, modified — The example has been deleted.]